Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00816517 · ClinicalTrials.gov registry record · Phase 1
Use of Botulinum Toxin to Treat Psoriasis
A Phase 1 study of Psoriasis Vulgaris, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT00816517: Completed Phase 1 study of Psoriasis Vulgaris, sponsored by University of Minnesota.
NCT00816517 is a Phase 1 study of Psoriasis Vulgaris that has completed, run by University of Minnesota. The registered enrollment target is 8 participants, below the 91-participant average among 6 other Psoriasis Vulgaris trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00816517, a Phase 1 study of Psoriasis Vulgaris, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
Psoriasis vulgaris is a chronic disease in which psoriatic plaques may appear on the knees, elbows, scalp and trunk. Evidence suggests the role of neurogenic inflammation in the pathogenesis of psoriasis. Botulinum toxin has been shown to have an effect on inhibiting neurogenic inflammation. Recently, it was reported that patients who suffered from dystonia and had concomitant psoriasis, when treated with botulinum toxin for dystonia noted a dramatic improvement of their psoriatic lesions. This pilot study will determine the safety and efficacy of botulinum toxin in the management of psoriasis vulgaris.
Conditions Studied
Interventions
- BIOLOGICAL injection of botulinum toxin type A.
Study Locations (1)
Minnesota
- Univerisity of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2009-01 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
What the finished NCT00816517 record still lists
NCT00816517 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 91-participant average among 6 other Psoriasis Vulgaris trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Psoriasis Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which injection of botulinum toxin type A. is the first listed.
NCT00816517 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00816517 about?
NCT00816517 is a clinical study titled "Use of Botulinum Toxin to Treat Psoriasis". Psoriasis vulgaris is a chronic disease in which psoriatic plaques may appear on the knees, elbows, scalp and trunk. Evidence suggests the role of neurogenic inflammation in the pathogenesis of psoriasis. Botulinum toxin has been shown to have an effect on inhibiting neurogenic inflammation. Recent...
What is the current status of trial NCT00816517?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2009-01. Estimated completion is 2015-12.
What conditions does trial NCT00816517 study?
This clinical trial studies the following conditions: Psoriasis Vulgaris.
What interventions are being tested in trial NCT00816517?
The interventions under investigation include: injection of botulinum toxin type A. (BIOLOGICAL).
Who is sponsoring clinical trial NCT00816517?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00816517 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris
COMPLETED · Phase 1
-
Correction of Psoriatic T Cell Signatures by Deucravacitinib
RECRUITING · Phase 4
-
Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)
RECRUITING · Phase 3
-
Blue Light Phototherapy
COMPLETED · NA
-
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
COMPLETED · Phase 2
-
Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia